The 5-year follow-up was not yet finished in cohort C; therefore, only cohort B was compared with cohort A in the analyses of 5-year survival time. The 5-year survival rates with native liver in cohorts A and B were 37.5% and 64.3%, respectively (P = 0.01). The 5-year

jaundice-free survival RG7420 rate with native liver was significantly higher in cohort B than in cohort A (64.3% versus 27.3%; P < 0.001) and the 5-year overall survival rates were 89.3% and 55.7%, respectively (P < 0.001). However, 15 cases in cohort B+C, despite their birth after the launch of the stool card screening program, were not successfully screened using the stool card. In order to clearly demonstrate PD 332991 the effect of the stool card screening program, we further analyzed the outcome by redividing our total cases from 1990 to 2005 into two groups for comparison: one group representing BA children without the screening program or not screened out by the stool card, the other group representing BA children who benefited from stool card screening (Supplement Table 1). The results are similar to the comparisons of cohort A and cohort B+C (Table 1). Logistic regression analyses revealed that patients who underwent Kasai operation before 60 days of age had a higher jaundice-free

rate at 3 months after surgery compared with those who underwent surgery after 60 days of age (odds ratio [OR] 2.62; P = 0.001) (Table 2). Patients born in the stool card screening era (cohort B+C) had a significantly higher jaundice-free rate at 3 months postsurgery than patients born before the screening era (cohort A) (OR 2.90; P < 0.001). The 3-year survival rates with native liver in patients who received Kasai operation before 60 days of age and after 60 days of age were 64.9% and 46.3%, respectively (OR 2.15; 95% confidence interval [CI] 1.19-3.86; P = 0.01). The 5-year survival rates with native liver in

patients who underwent surgery before 60 days old and after 60 days old were 上海皓元 55.0% and 32.1%, respectively (OR 2.58; 95% CI 1.21-5.50; P = 0.01). The 3-year survival rates with native liver in patients who were and were not jaundice-free at 3 months after Kasai operation were 84.9% and 30.6%, respectively (OR 12.79; 95% CI 6.27-26.08; P < 0.001). The 5-year survival rates with native liver in patients who were and were not jaundice-free at 3 months postsurgery were 77.6% and 19.4%, respectively (OR 14.35; 95% CI 5.81-35.43; P < 0.001). Jaundice-free survival with native liver was considered as quality outcome. Cohort B+C had higher rates of 3- and 5-year jaundice-free survival with native liver than cohort A (OR 2.87, P = 0.001, and OR 4.80, P = 0.001, respectively) (Table 3). Patients who received Kasai operation before 60 days of age had better 3- and 5-year jaundice-free survival with native liver than patients who received an operation after 60 days of age (OR 3.25, P < 0.001 and OR 2.63, P = 0.